Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CNS

This article was originally published in The Tan Sheet

Executive Summary

Breathe Right nasal strip maker will not launch new products in remainder of 2001, focusing instead on core brands including Fiberchoice chewable fiber product. Strong international growth, distribution helps firm achieve 85% top-line sales growth to $27.1 mil. in first quarter, CNS tells analysts April 19. International sales soared to $4.8 mil. from $296,000 in prior-year period. Breathe Right revenues rose 39% in quarter, primarily due to new strips with Vicks "mentholated vapors" and children's strips with graphics, COO/President Marti Morfitt notes. Direct response ad broke week of April 16 focusing on Breathe Right for allergies, an indication CNS plans to highlight into 2002, Morfitt says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel